Oncocross, an AI-based drug development biotech, announced that it initiated a phase I global clinical trial for ‘OC514’ targeting muscular diseases including sarcopenia. Oncocross obtained Australia’s Therapeutic Goods Administration (“TGA”) approval on phase I IND application for OC514 on February 14, 2022 and began a clinical trial with healthy adults in Australia on February 23, 2022. The clinical study aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of OC514...